Sign In
to Vote &
Create Storyboards.
 

New treatments aim to combat renal cell cancer and melanoma

Medical News Today - 25 Sep 2013 11:00
Renal cell cancer vaccines Immatics Biotechnologies' cancer vaccine IMA901 is currently in phase III trials for the first-line treatment of metastatic renal cell cancer. The drug, which was shown to have a positive safety profile in its single-arm Phase II trial, is expected to gain approval in the US and five major EU markets* by 2015. It's estimated that IMA901 will be worth $88m by 2022, but is likely to face competition from Argos therapeutics/Kyowa HakkoKirin's AGS-003 which is currently at...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard